A risk score for prediction of venous thromboembolism in gynecologic cancer: The Thrombogyn score.
Authors
Norris, Lucy AWard, Mark P
O'Toole, Sharon A
Marchocki, Zibi
Ibrahim, Nadia
Khashan, Ali S
Abu Saadeh, Feras
Gleeson, Noreen
Issue Date
2020-05-28Keywords
biomarkersCANCER
RISK
thrombin
venous thromboembolism
WOMEN
Metadata
Show full item recordJournal
Research and practice in thrombosis and haemostasisDOI
10.1002/rth2.12342PubMed ID
32685894Abstract
Background: Gynecologic cancers are associated with high rates of venous thromboembolism (VTE), which is exacerbated by pelvic surgery and chemotherapy. Objectives: The aim of this study was to develop and validate a risk score for VTE in patients with gynecologic cancer and to test the predictive ability of the score following addition of procoagulant biomarker data. Patients and methods: Clinical and laboratory variables were used to develop a risk score for the prediction of VTE in patients with gynecological cancer (n = 616), which was validated in a separate cohort of patients (n = 406). Endogenous thrombin potential and D-dimer levels were determined in a subset (n = 290) of patients and used to produce an extended score in the validation cohort. Results: Multivariable regression analysis identified BMI >30, hemoglobin <11.5 g/dL and chemotherapy as independent predictors of VTE, which formed the Thrombogyn score. Following competing risk regression analysis, subdistribution hazard ratios (SHRs), adjusted for cancer stage, were 8.16 (95% confidence interval [CI], 1.69-43.77) in the high-risk group (score = 2-3) and 4.12 (95% CI, 0.85-20.15) in the intermediate-risk group (score = 1) compared with the low-risk group (score = 0). SHRs for the validation cohort were 6.26 (95% CI, 1.24-31.39) and 3.00 (95% CI, 0.67-13.32), respectively. Cumulative incidence of VTE in the validation cohort high-risk group was 10.34% (95% CI, 6.51-16.41) per women-years compared with 1.06% (95% CI, 0.26-4.26) in the low-risk group. Using the extended Thrombogyn score, adjusted SHRs were 16.83 (95% CI, 4.20-67.37) in the high-risk group with a cumulative incidence of 21.15% (95% CI, 10.32-45.24). External validation of the score is required. Conclusions: The Thrombogyn score identifies patients with gynecologic cancer at high and low risk of VTE. Addition of biomarker data improves the predictive power of the score.Item Type
ArticleLanguage
enEISSN
2475-0379ae974a485f413a2113503eed53cd6c53
10.1002/rth2.12342
Scopus Count
Collections
Related articles
- Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score.
- Authors: Chakraborty R, Rybicki L, Wei W, Valent J, Faiman BM, Samaras CJ, Anwer F, Khorana AA
- Issue date: 2022 Dec 8
- Derivation, validation and assessment of a novel nomogram-based risk assessment model for venous thromboembolism in hospitalized patients with lung cancer: A retrospective case control study.
- Authors: Li H, Tian Y, Niu H, He L, Cao G, Zhang C, Kaiweisierkezi K, Luo Q
- Issue date: 2022
- Application value of Caprini risk assessment model and elevated tumor-specific D-dimer level in predicting postoperative venous thromboembolism for patients undergoing surgery of gynecologic malignancies.
- Authors: Shi J, Ye J, Zhuang X, Cheng X, Fu R, Zhao A
- Issue date: 2019 Mar
- A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts.
- Authors: Pabinger I, van Es N, Heinze G, Posch F, Riedl J, Reitter EM, Di Nisio M, Cesarman-Maus G, Kraaijpoel N, Zielinski CC, Büller HR, Ay C
- Issue date: 2018 Jul
- Venous Thrombosis Risk after Cast Immobilization of the Lower Extremity: Derivation and Validation of a Clinical Prediction Score, L-TRiP(cast), in Three Population-Based Case-Control Studies.
- Authors: Nemeth B, van Adrichem RA, van Hylckama Vlieg A, Bucciarelli P, Martinelli I, Baglin T, Rosendaal FR, le Cessie S, Cannegieter SC
- Issue date: 2015 Nov